Drug Profile
Motixafortide - Biokine Therapeutics/BioLineRx
Alternative Names: 4F-Benzoyl-TN14003; APHEXDA; BKT-140; BL-8040; GFH-168; TF-14016; TN-14003Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Kyoto University
- Developer Biokine Therapeutics; BioLineRx; Genentech; Merck & Co
- Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
- Mechanism of Action Apoptosis stimulants; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Stem cell mobilisation
- Phase II Acute myeloid leukaemia; Aplastic anaemia; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Gastric cancer
- No development reported Adult respiratory distress syndrome
- Discontinued Chronic myeloid leukaemia; Thrombocytopenia
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Adult-respiratory-distress-syndrome in Israel (Parenteral)
- 26 Mar 2024 Launched for Stem cell mobilisation (Combination therapy) in USA (SC) - First Global Launch
- 26 Mar 2024 BioLineRx in collaboration with Gloria Biosciences files an IND application with the NMPA in China for Stem cell mobilization in February 2024